# Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis

> **NCT01214564** · PHASE2 · COMPLETED · sponsor: **Peplin** · enrollment: 24 (actual)

## Conditions studied

- Seborrheic Keratosis

## Interventions

- **DRUG:** PEP005 (ingenol mebutate) Gel

## Key facts

- **NCT ID:** NCT01214564
- **Lead sponsor:** Peplin
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2011-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01214564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01214564, "Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01214564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*